Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

377
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
377
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

482
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
482
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

337
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
337
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

750
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
750
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

16.8K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.8K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.5K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial.

British journal of haematology·2026
Same author

Prevalence, pattern and prognosis of lung lesions in pediatric Hodgkin lymphoma.

Scientific reports·2026
Same author

E Lesion or Stage IV disease? An Ongoing Unsettled Issue in Pediatric Hodgkin Lymphoma.

Blood advances·2026
Same author

Evaluation of Baseline and Interim-Therapy PET Features for Prognostication in High-Risk Pediatric Hodgkin Lymphoma: A Retrospective Analysis of the AHOD1331 Trial.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Development and pre-testing of a family-centered digital intervention to help families know what to EXPECT from pediatric acute lymphoblastic leukemia therapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

​EuroNet-PHL-LP1: Complete resection or low-dose chemo for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.

Blood advances·2026

Related Experiment Video

Updated: Apr 5, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

849

Pediatric Hodgkin Lymphoma.

Christine Mauz-Körholz1, Monika L Metzger2, Kara M Kelly2

  • 1Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany. christine.mauz-koerholz@uk-halle.de.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|August 26, 2015
PubMed
Summary

Pediatric Hodgkin lymphoma (HL) treatment advances improve survival but increase risks for survivors. Harmonizing criteria is crucial for standardizing risk stratification and improving care globally.

More Related Videos

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

41.5K
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.6K

Related Experiment Videos

Last Updated: Apr 5, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

849
Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

41.5K
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.6K

Area of Science:

  • Pediatric Oncology
  • Cancer Treatment and Survivorship

Background:

  • Hodgkin lymphoma (HL) is a highly curable cancer in children and adults, with survival rates over 90% with chemotherapy and radiotherapy (RT).
  • Survivors of pediatric HL face significant risks of secondary cancers and cardiovascular disease due to treatment toxicity.
  • Global collaboration in clinical trials has driven progress, focusing on response-based treatment adaptation and toxicity reduction.

Purpose of the Study:

  • To highlight the progress in pediatric Hodgkin lymphoma treatment through collaborative efforts.
  • To emphasize the need for harmonized staging and response criteria for comparing trial results and improving global care.
  • To advocate for a dynamic harmonization process to standardize risk stratification and response definitions.

Main Methods:

  • Review of treatment paradigms and outcomes from major pediatric and adult HL study groups over three decades.
  • Analysis of strategies for toxicity sparing, including reduction/elimination of RT and tailored chemotherapy.
  • Identification of challenges in comparing trial series due to non-uniform pediatric staging and response criteria.

Main Results:

  • High treatment efficacy achieved with dose-dense chemotherapy and reduced or eliminated radiotherapy for certain patient subgroups.
  • Continued progress in HL treatment driven by cooperative group studies and response-based adaptation.
  • Difficulty in comparing results across different study groups due to lack of uniform criteria.

Conclusions:

  • Harmonization of pediatric staging and response criteria is essential for accurate comparison of trial results and advancement of care.
  • Standardizing therapeutic risk stratification and response definitions will improve the management of pediatric HL, especially in resource-limited settings.
  • A dynamic harmonization process is critical for advancing the care and long-term outcomes for children with Hodgkin lymphoma.